Pulmonary Manifestations of Polymyositis/Dermatomyositis

 

 Permissions and Reprints

Abstract

The idiopathic inflammatory myopathies are a group of connective tissue diseases marked by varying degrees of muscle inflammation and clinical involvement of multiple organs, most notably, the lung. Pulmonary manifestations consist primarily of interstitial lung disease (ILD), which is associated with significant morbidity and mortality in myositis patients. Several myositis-specific antibodies have been discovered, as well as antibodies targeting various aminoacyl-tRNA synthetase enzymes. These antibodies are associated with various clinical features and a risk for developing ILD, and their presence carries a prognostic value in myositis patients. Steroids remain the first-line treatment for myositis-associated ILD and the antisynthetase syndrome, though other traditional immunosuppressants have demonstrated efficacy in numerous studies. While a majority of patients experience either stabilization or improvement in lung imaging and function, fatal progression is still reported in a significant number of cases. Further research is needed to develop more effective and targeted therapies.

• References

• 1 Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine L, Danoff SK, Oddis CV. Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rep 2010; 6 (2) 108-119
  CrossrefPubMedGoogle Scholar
• 2 Chen IJ, Jan Wu YJ, Lin CW , et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009; 28 (6) 639-646
  CrossrefPubMedGoogle Scholar
• 3 Ye S, Chen XX, Lu XY , et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 2007; 26 (10) 1647-1654
  CrossrefPubMedGoogle Scholar
• 4 Won Huh J, Soon Kim D, Keun Lee C , et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 2007; 101 (8) 1761-1769
  CrossrefPubMedGoogle Scholar
• 5 Hayashi S, Tanaka M, Kobayashi H , et al. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J Rheumatol 2008; 35 (2) 260-269
  PubMedGoogle Scholar
• 6 Yu KH, Wu YJ, Kuo CF , et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol 2011; 30 (12) 1595-1601
  CrossrefPubMedGoogle Scholar
• 7 Ji SY, Zeng FQ, Guo Q , et al. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study. Chin Med J (Engl) 2010; 123 (5) 517-522
  PubMedGoogle Scholar
• 8 Fathi M, Vikgren J, Boijsen M , et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59 (5) 677-685
  CrossrefPubMedGoogle Scholar
• 9 Chua F, Higton AM, Colebatch AN , et al. Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort. Rheumatology (Oxford) 2012; 51 (10) 1870-1876
  CrossrefPubMedGoogle Scholar
• 10 Lee CS, Chen TL, Tzen CY , et al. Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol 2002; 21 (5) 391-396
  CrossrefPubMedGoogle Scholar
• 11 Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004; 63 (3) 297-301
  CrossrefPubMedGoogle Scholar
• 12 Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292 (8) 403-407
  CrossrefPubMedGoogle Scholar
• 13 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292 (7) 344-347
  CrossrefPubMedGoogle Scholar
• 14 Koreeda Y, Higashimoto I, Yamamoto M , et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med 2010; 49 (5) 361-369
  CrossrefPubMedGoogle Scholar
• 15 Marie I, Josse S, Hatron PY , et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2013; 65 (5) 800-808
  CrossrefPubMedGoogle Scholar
• 16 Sato S, Hirakata M, Kuwana M , et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52 (5) 1571-1576
  CrossrefPubMedGoogle Scholar
• 17 Kaji K, Fujimoto M, Hasegawa M , et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46 (1) 25-28
  CrossrefPubMedGoogle Scholar
• 18 Brouwer R, Hengstman GJ, Vree Egberts W , et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001; 60 (2) 116-123
  CrossrefPubMedGoogle Scholar
• 19 Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50 (1) 209-215
  CrossrefPubMedGoogle Scholar
• 20 Dugar M, Cox S, Limaye V, Blumbergs P, Roberts-Thomson PJ. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Intern Med J 2011; 41 (9) 674-679
  CrossrefPubMedGoogle Scholar
• 21 Kalluri M, Sahn SA, Oddis CV , et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 2009; 135 (6) 1550-1556
  CrossrefPubMedGoogle Scholar
• 22 Hirakata M, Suwa A, Nagai S , et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999; 162 (4) 2315-2320
  PubMedGoogle Scholar
• 23 Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 2007; 46 (6) 1005-1008
  CrossrefPubMedGoogle Scholar
• 24 Kunimasa K, Arita M, Nakazawa T , et al. The clinical characteristics of two anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody-positive interstitial lung disease patients with polymyositis/dermatomyositis. Intern Med 2012; 51 (24) 3405-3410
  CrossrefPubMedGoogle Scholar
• 25 Hervier B, Meyer A, Dieval C , et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. Eur Respir J 2013; 42 (5) 1271-1282
  CrossrefPubMedGoogle Scholar
• 26 Marie I, Josse S, Decaux O , et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012; 11 (10) 739-745
  CrossrefPubMedGoogle Scholar
• 27 Hamaguchi Y, Fujimoto M, Matsushita T , et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE 2013; 8 (4) e60442
  CrossrefPubMedGoogle Scholar
• 28 Hall JC, Casciola-Rosen L, Samedy LA , et al. Anti-MDA5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013; 65 (8) 1307-1315
  PubMedGoogle Scholar
• 29 Hervier B, Benveniste O. Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep 2013; 15 (8) 349
  CrossrefPubMedGoogle Scholar
• 30 Gono T, Kawaguchi Y, Kuwana M , et al. Brief report: association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum 2012; 64 (11) 3736-3740
  CrossrefPubMedGoogle Scholar
• 31 Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007; 19 (6) 523-529
  CrossrefPubMedGoogle Scholar
• 32 Marie I, Hatron PY, Dominique S , et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 2012; 41 (6) 890-899
  CrossrefPubMedGoogle Scholar
• 33 Richards TJ, Eggebeen A, Gibson K , et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum 2009; 60 (7) 2183-2192
  CrossrefPubMedGoogle Scholar
• 34 Marie I, Josse S, Decaux O , et al. Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome. Eur J Intern Med 2013; 24 (5) 474-479
  CrossrefPubMedGoogle Scholar
• 35 Hervier B, Wallaert B, Hachulla E , et al. Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford) 2010; 49 (5) 972-976
  CrossrefPubMedGoogle Scholar
• 36 Sato S, Hoshino K, Satoh T , et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60 (7) 2193-2200
  CrossrefPubMedGoogle Scholar
• 37 Chen F, Wang D, Shu X, Nakashima R, Wang G. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int 2012; 32 (12) 3909-3915
  CrossrefPubMedGoogle Scholar
• 38 Cao H, Pan M, Kang Y , et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken) 2012; 64 (10) 1602-1610
  CrossrefPubMedGoogle Scholar
• 39 Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65 (1) 25-34
  CrossrefPubMedGoogle Scholar
• 40 Kang EH, Nakashima R, Mimori T , et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 2010; 11: 223
  CrossrefPubMedGoogle Scholar
• 41 Koga T, Fujikawa K, Horai Y , et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 2012; 51 (7) 1278-1284
  CrossrefPubMedGoogle Scholar
• 42 Fujikawa K, Kawakami A, Kaji K , et al. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol 2009; 38 (4) 263-267
  CrossrefPubMedGoogle Scholar
• 43 Gono T, Sato S, Kawaguchi Y , et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 2012; 51 (9) 1563-1570
  CrossrefPubMedGoogle Scholar
• 44 Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010; 49 (9) 1726-1733
  CrossrefPubMedGoogle Scholar
• 45 Ikeda N, Takahashi K, Yamaguchi Y, Inasaka M, Kuwana M, Ikezawa Z. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol 2011; 38 (10) 973-979
  CrossrefPubMedGoogle Scholar
• 46 Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford) 2012; 51 (5) 800-804
  CrossrefPubMedGoogle Scholar
• 47 Sato S, Kuwana M, Fujita T, Suzuki Y. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol 2012; 22 (4) 625-629
  CrossrefPubMedGoogle Scholar
• 48 Selva-O'Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar CP, Martínez-Gómez X, Vilardell-Tarrés M. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 2006; 55 (5) 791-798
  CrossrefPubMedGoogle Scholar
• 49 Venables PJ. Polymyositis-associated overlap syndromes. Br J Rheumatol 1996; 35 (4) 305-306
  CrossrefPubMedGoogle Scholar
• 50 Lega JC, Cottin V, Fabien N, Thivolet-Béjui F, Cordier JF. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?. J Rheumatol 2010; 37 (5) 1000-1009
  CrossrefPubMedGoogle Scholar
• 51 Ferreira JP, Almeida I, Marinho A, Cerveira C, Vasconcelos C. Anti-ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma. ISRN Rheumatol 2012; 2012: 415272
  PubMedGoogle Scholar
• 52 Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997; 109 (1) 32-40
  CrossrefPubMedGoogle Scholar
• 53 Dugar M, Cox S, Limaye V, Gordon TP, Roberts-Thomson PJ. Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 2010; 86 (1012) 79-82
  CrossrefPubMedGoogle Scholar
• 54 La Corte R, Lo Mo Naco A, Locaputo A, Dolzani F, Trotta F. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 2006; 39 (3) 249-253
  CrossrefPubMedGoogle Scholar
• 55 Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009; 48 (6) 607-612
  CrossrefPubMedGoogle Scholar
• 56 Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990; 33 (9) 1361-1370
  CrossrefPubMedGoogle Scholar
• 57 Hengstman GJ, ter Laak HJ, Vree Egberts WT , et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65 (12) 1635-1638
  CrossrefPubMedGoogle Scholar
• 58 Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73 (4) 420-428
  CrossrefPubMedGoogle Scholar
• 59 Hengstman GJ, Vree Egberts WT, Seelig HP , et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 2006; 65 (2) 242-245
  CrossrefPubMedGoogle Scholar
• 60 Wang HB, Zhang Y. Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor. Nucleic Acids Res 2001; 29 (12) 2517-2521
  CrossrefPubMedGoogle Scholar
• 61 Chinoy H, Salway F, Fertig N , et al; UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC). In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 8 (1) R13
  CrossrefPubMedGoogle Scholar
• 62 Gono T, Kawaguchi Y, Satoh T , et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 2010; 49 (9) 1713-1719
  CrossrefPubMedGoogle Scholar
• 63 Tanizawa K, Handa T, Nakashima R , et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 2013; 107 (5) 745-752
  CrossrefPubMedGoogle Scholar
• 64 Ideura G, Hanaoka M, Koizumi T , et al. Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. Respir Med 2007; 101 (7) 1406-1411
  CrossrefPubMedGoogle Scholar
• 65 Fujisawa T, Suda T, Nakamura Y , et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005; 32 (1) 58-64
  PubMedGoogle Scholar
• 66 Hervier B, Devilliers H, Stanciu R , et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012; 12 (2) 210-217
  CrossrefPubMedGoogle Scholar
• 67 Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011; 63 (11) 3439-3447
  CrossrefPubMedGoogle Scholar
• 68 Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med 2012; 271 (6) 589-597
  CrossrefPubMedGoogle Scholar
• 69 Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?. Chest 2010; 138 (6) 1464-1474
  CrossrefPubMedGoogle Scholar
• 70 Le Goff B, Chérin P, Cantagrel A , et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis Rheum 2009; 61 (1) 108-118
  PubMedGoogle Scholar
• 71 Kono H, Inokuma S, Nakayama H, Suzuki M. Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy. Ann Rheum Dis 2000; 59 (5) 372-376
  CrossrefPubMedGoogle Scholar
• 72 Korkmaz C, Ozkan R, Akay M, Hakan T. Pneumomediastinum and subcutaneous emphysema associated with dermatomyositis. Rheumatology (Oxford) 2001; 40 (4) 476-478
  CrossrefPubMedGoogle Scholar
• 73 Maruoka H, Honda S, Takeo M , et al. A case of polymyositis complicated with interstitial pneumonitis and pneumomediastinum. Mod Rheumatol 2006; 16 (1) 55-57
  CrossrefPubMedGoogle Scholar
• 74 Park SH, Kum YS, Kim KC, Choe JY, Park SH, Kim SK. Pneumomediastinum and subcutaneous emphysema secondary to amyopathic dermatomyositis with cryptogenic organizing pneumonia in invasive breast cancer: a case report and review of literature. Rheumatol Int 2009; 29 (10) 1231-1235
  CrossrefPubMedGoogle Scholar
• 75 Powell C, Kendall B, Wernick R, Heffner JE. A 34-year-old man with amyopathic dermatomyositis and rapidly progressive dyspnea with facial swelling. Diagnosis: pneumomediastinum and subcutaneous emphysema secondary to amyopathic dermatomyositis-associated interstitial lung disease. Chest 2007; 132 (5) 1710-1713
  CrossrefPubMedGoogle Scholar
• 76 Sandhya P, Keshava SN, Danda D, Padhan P, Mathew J, Gibikote S. Pneumorrhachis and pneumomediastinum in connective tissue disease-related interstitial lung disease: case series from a tertiary care teaching hospital in South India. Rheumatol Int 2012; 32 (5) 1415-1419
  CrossrefPubMedGoogle Scholar
• 77 Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology (Oxford) 2007; 46 (5) 842-845
  CrossrefPubMedGoogle Scholar
• 78 Yoshifuji H, Fujii T, Kobayashi S , et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 39 (3) 233-241
  CrossrefPubMedGoogle Scholar
• 79 Hamaguchi Y, Kuwana M, Hoshino K , et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011; 147 (4) 391-398
  CrossrefPubMedGoogle Scholar
• 80 Kameda H, Nagasawa H, Ogawa H , et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005; 32 (9) 1719-1726
  PubMedGoogle Scholar
• 81 Swigris JJ, Olson AL, Fischer A , et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130 (1) 30-36
  CrossrefPubMedGoogle Scholar
• 82 Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62 (10) 1496-1501
  CrossrefPubMedGoogle Scholar
• 83 Yamasaki Y, Yamada H, Yamasaki M , et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007; 46 (1) 124-130
  CrossrefPubMedGoogle Scholar
• 84 Ingegnoli F, Lubatti C, Ingegnoli A, Boracchi P, Zeni S, Meroni PL. Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev 2012; 11 (5) 335-340
  CrossrefPubMedGoogle Scholar
• 85 Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005; 38 (5) 383-392
  CrossrefPubMedGoogle Scholar
• 86 Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52 (8) 2439-2446
  CrossrefPubMedGoogle Scholar
• 87 Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009; 48 (8) 968-971
  CrossrefPubMedGoogle Scholar
• 88 Park JK, Yoo HG, Ahn DS, Jeon HS, Yoo WH. Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatol Int 2012; 32 (11) 3587-3590
  CrossrefPubMedGoogle Scholar
• 89 Suzuki Y, Hayakawa H, Miwa S , et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 2009; 187 (3) 201-206
  CrossrefPubMedGoogle Scholar
• 90 Bakewell CJ, Raghu G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 2011; 139 (2) 441-443
  CrossrefPubMedGoogle Scholar
• 91 Gono T, Kawaguchi Y, Hara M , et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 2010; 49 (7) 1354-1360
  CrossrefPubMedGoogle Scholar
• 92 Tillie-Leblond I, Wislez M, Valeyre D , et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008; 63 (1) 53-59
  CrossrefPubMedGoogle Scholar
• 93 Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007; 9 (4) R78
  CrossrefPubMedGoogle Scholar
• 94 Mukae H, Ishimoto H, Sakamoto N , et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009; 136: 1341-1347
  CrossrefPubMedGoogle Scholar